The firm's financial position is deteriorating, with total assets contracting to $16.2 million in 2026Q1 and the current ratio narrowing to 1.27 from a 2025Q1 peak of 10.68.
| Total Current Assets | 16.24M | 21.08M | 13.93M | 10.21M | 36.02M | 46M | 8.12M | 747.51K | 50.99K | 357.96K |
| Cash & Short-Term Investments | 14.22M | 19.53M | 10.55M | 5.75M | 28.38M | 45.69M | 8.07M | 1.86K | 35.31K | 347.47K |
| Cash Only | 14.22M | 19.53M | 10.55M | 5.75M | 28.38M | 45.69M | 8.07M | 1.86K | 35.31K | 347.47K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 735.08K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -745.64M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 7.5K | 0 | 7.5K | 20.8K | 7.54M | 9.87K | 6.44K | 745.65M | 0 | 0 |
| Total Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 369.6K | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 369.6K | 0 | 0 |
| Total Assets | 16.24M | 21.08M | 13.93M | 10.21M | 36.02M | 46M | 8.12M | 1.12M | 50.99K | 357.96K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 356.97% | 51.39% | 36.42% | -71.66% | -21.69% | 466.57% | 626.82% | 2090.75% | -85.76% | - |
| Total Current Liabilities | 12.79M | 3.64M | 3.88M | 4.28M | 7.7M | 1.51M | 578.38K | 2.01M | 567.94K | 490.22K |
| Accounts Payable | 5.28M | 2.59M | 2.31M | 1.29M | 3.96M | 688.07K | 341.86K | 1.23M | 68.42K | 71.11K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.78M | 1.04M | 1.21M | 273 | 0 | 105.67K | 220.03K | 645.34K | 477.88K | 415.35K |
| Current Ratio | 1.27x | 5.80x | 3.59x | 2.39x | 4.68x | 30.54x | 14.04x | 0.37x | 0.09x | 0.73x |
| Quick Ratio | 1.27x | 5.80x | 3.59x | 2.39x | 4.68x | 30.54x | 14.04x | 371.20x | 0.09x | 0.73x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 327K | 595K | 737K | 13.68M | 0 | 0 | 0 | 7.68M | 7.08M | 6.83M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 499.81K | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 327K | 595K | 737K | 13.68M | 0 | 0 | 0 | 7.18M | 7.08M | 6.83M |
| Total Liabilities | 13.12M | 4.23M | 4.62M | 17.96M | 7.7M | 1.51M | 578.38K | 9.69M | 7.64M | 7.32M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 499.81K | 0 | 0 |
| Net Debt | -14.22M | -19.53M | -10.55M | -5.75M | -28.38M | -45.69M | -8.07M | 497.95K | -35.31K | -347.47K |
| Debt / Equity | 0.00x | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.34x | - | - | - | - | - | - | - | - | -802.48x |
| Interest Coverage | - | - | -14.40x | - | - | - | -0.14x | - | -10818.18x | -8119.05x |
| Total Equity | 3.13M | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M | 7.54M | -8.58M | -7.59M | -6.97M |
| Equity Growth % | 1227.22% | 81.05% | 220.09% | -127.37% | -36.34% | 490.04% | 187.93% | -12.94% | -9.02% | - |
| Book Value per Share | 0.11 | 0.82 | 0.76 | -0.86 | 3.47 | 5.83 | 1.20 | -1.25 | -1.73 | -1.58 |
| Total Shareholders' Equity | 3.13M | 16.85M | 9.31M | -7.75M | 28.32M | 44.49M | 7.54M | -8.58M | -7.59M | -6.97M |
| Common Stock | 2.85K | 2.72K | 1.41K | 1.05K | 816 | 810 | 689 | 0 | 0 | 0 |
| Retained Earnings | -181.31M | -163.7M | -134.85M | -110.26M | -54.05M | -28.73M | -14.24M | -8.78M | -7.79M | -7.07M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7.08M | -7.08M | -6.83M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Binary clinical trial failure
As reported in financial statements, Annovis Bio's total assets have contracted from $26.7 million in 2025Q1 to $16.2 million by 2026Q1, reflecting a persistent depletion of resources as the company attempts to fund late-stage clinical development without any offsetting commercial revenue streams to stabilize its financial position.
The downward trend in total assets suggests that the company is consuming its capital base at a rate that outpaces its ability to replenish it through non-dilutive means. This trajectory implies that the firm is approaching a critical juncture where the balance sheet may no longer support the current intensity of its research programs.
Based on ANVS's reported figures, the current ratio has deteriorated significantly from a peak of 10.68 in 2025Q1 to 1.27 in 2026Q1, indicating that the company's cash runway is narrowing rapidly as it funds the high-cost requirements of its ongoing Phase 3 clinical trials.
The sharp decline in the current ratio highlights a diminishing margin of safety against unexpected operational costs or delays in trial enrollment. Investors should monitor whether the current cash balance of $14.2 million is sufficient to sustain operations through the next major data readout without necessitating further dilutive financing.
According to recent SEC filings, the company's equity position has been severely eroded by accumulated deficits, which reached $181.3 million in 2026Q1, underscoring the substantial value destruction inherent in a pre-revenue biotech model that relies entirely on external capital to sustain its research and development activities.
The negative trend in retained earnings reflects the ongoing cost of clinical development and the lack of commercialization. This persistent erosion of equity suggests that shareholders are bearing the full brunt of the company's R&D-heavy business model, with little evidence of value creation until clinical milestones are achieved.
As indicated by the company's financial statements, the balance sheet is almost entirely composed of cash and short-term assets, with zero PPE or goodwill, which suggests that the firm's entire value is tied to intangible intellectual property that remains unproven in large-scale clinical settings.
The absence of tangible assets implies that the company has no fallback value if its lead compound, Buntanetap, fails to meet primary endpoints. This structure makes the balance sheet highly sensitive to binary clinical outcomes, as there are no physical assets to provide a floor for the company's valuation.
Quick answers to the most common questions about buying ANVS stock.
As of 2025, Annovis Bio, Inc. (ANVS) had total assets of $21.1M including $21.1M in current assets.
Annovis Bio, Inc. (ANVS) carries total debt of $0.0M, offset by $19.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Annovis Bio, Inc. (ANVS) has total shareholders' equity (book value) of $16.9M ($0.82 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Annovis Bio, Inc. (ANVS) reported a current ratio of 5.80x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.